Operations · Public Status · Updated 2026-05-19

503A pharmacy partner status update.

A running, public scorecard on the two-partner 503A compounding pharmacy commitment Limitless made on /why-physician-led. Updated whenever the status changes.
Status · On track, in active negotiation As of 2026-05-19 · Two pharmacy conversations active.

The commitment.

On April 23, 2026, the FDA reclassified twelve compounded peptides — including BPC-157, TB-500, ipamorelin, and several others on the GH-axis and recovery panels. Same week, Limitless committed publicly on /why-physician-led to a specific operational standard: two qualified 503A compounding pharmacy partners under written agreement no later than June 1, 2026, with the audit checklist published, redundancy in supply, and chain-of-custody documentation for every dose dispensed to a Limitless patient.

This page exists so anyone — a patient, a future regulator, a competitor — can see where that commitment actually stands at any point in time. We update it within 48 hours of any material change.

Partner pipeline.

Partner A — Tier 1 (lead candidate)

Pharmacist call complete · Pending signed MOU
Initial outreach 2026-05-14 · pharmacist call 2026-05-16 · written agreement in counsel review
  • Capabilities verifiedBPC-157, TB-500, MOTS-c, ipamorelin, tesamorelin (compounded), sermorelin
  • 503A accreditationActive · USP <797> / <800> compliant · per-lot CoA
  • State licensureGeorgia non-resident pharmacy license verified
  • Sterility & stabilityBUD documentation furnished for lyophilized GH-axis peptides
  • Open itemsFinal MOU language; chain-of-custody data exchange spec
  • Expected signing window2026-05-22 to 2026-05-26

Partner B — Tier 1 (redundancy / failover)

Cold-email response received · Pharmacist call scheduled
Initial outreach 2026-05-14 · response 2026-05-17 · 30-min pharmacist call scheduled 2026-05-21
  • Capabilities expectedBPC-157, TB-500, MOTS-c, ipamorelin (pending PCAC outcome), sermorelin, NAD+
  • 503A accreditationActive per public filings · USP <797> / <800> assumed; verification pending call
  • State licensureGeorgia non-resident pharmacy license verification pending
  • Open itemsFull formulary, stability data, MOU template review
  • Expected signing window2026-05-28 to 2026-06-01

Backup partners (warm bench)

Two named, available if A or B falls through
Identified in the 2026-05-14 operations packet · not yet engaged

Two additional 503A pharmacies have been identified as backups in case Partner A or B fails the audit or declines to sign. These remain unnamed publicly until and unless engaged, to avoid premature association on either side.

Timeline.

  • 2026-04-23 FDA peptide reclassification announced. Limitless publishes operational posture (BPC-157, TB-500, ipamorelin back on formulary).
  • 2026-04-28 Two-partner commitment published on /why-physician-led.
  • 2026-05-03 503A pharmacy audit checklist completed.
  • 2026-05-13 CJC-1295 verification: not legal for human compounding in 2026. Standing protocol updated; FDA comment filed.
  • 2026-05-14 Outreach packet sent to two tier-1 pharmacy candidates. Backup list assembled.
  • 2026-05-16 Partner A — pharmacist call complete. Capabilities and accreditation verified.
  • 2026-05-17 Partner B — cold email response received. Pharmacist call scheduled.
  • 2026-05-21 Partner B — 30-minute pharmacist call (scheduled).
  • 2026-05-26 (expected) Partner A MOU signed.
  • 2026-06-01 (deadline) Two-partner public commitment honored — Partner A and Partner B under written agreement.
  • 2026-07-23 → 2026-07-24 FDA PCAC meeting (BPC-157, TB-500, KPV, MOTS-c day 1). Re-evaluate partner formularies on outcome.

What "on track" means.

We are using a three-color status convention on this page:

  • Green Two signed partners on file. Audit packet completed, written agreement on file, chain-of-custody data exchange tested. The June 1 commitment is honored.
  • Amber On track, in active negotiation. At least one pharmacist call complete; at least one MOU in counsel review. Expected signing inside the deadline window.
  • Red Deadline slip. If the June 1 commitment cannot be met, this page (and /why-physician-led) will be updated within 48 hours with a transparent explanation, a revised deadline, and a clinical-impact statement.
Why publish this at all? Because the operational standard is the differentiator. Anyone can put "physician-led" or "compliant" on a homepage. Publishing a running, dated scorecard against a specific commitment is the verifiable form of that claim. If Limitless misses the deadline, the page will say so before anyone has to ask.

How patients are affected.

In the interim — until Partner A is signed — Limitless is operating from a single qualified 503A pharmacy under a verbal handshake plus initial paperwork. This is workable at current patient volume, but it is the redundancy gap that the two-partner commitment exists to close.

Two practical impacts for current patients:

1. No protocol change is required pending Partner A or B signing. Current GH-axis recommendations (tesamorelin lead, sermorelin alternative, ipamorelin conditional) are unchanged.

2. Once Partner B is signed, patients who prefer a specific compounding pharmacy can request the assignment at no cost. Patients are not required to switch — but the option will be available.

Questions about your specific protocol or pharmacy assignment should be sent directly to Dr. Hare: hare.joshua42@gmail.com.